期刊
ANTIVIRAL RESEARCH
卷 134, 期 -, 页码 6-16出版社
ELSEVIER
DOI: 10.1016/j.antiviral.2016.08.014
关键词
Protease inhibitors; High-throughput screening; Renilla luciferase reporter replicon; Virus infectivity assays; Therapeutic index; Fluorescence quenching
资金
- National Institutes of Health [AI070791-03S1, U01-AI082068, R21AI109185]
- NIH grant [U54 AI057159]
- Biomedical Graduate Research Organization of Georgetown University
- Cosmos Club Foundation Young Scholars Award
- University Grants Commission, Govt of India
The mosquito-borne dengue virus serotypes 1-4 (DENV1-4) and West Nile virus (WNV) cause serious illnesses worldwide associated with considerable morbidity and mortality. According to the World Health Organization (WHO) estimates, there are about 390 million infections every year leading to similar to 500,000 dengue haemorrhagic fever (DHF) cases and similar to 25,000 deaths, mostly among children. Antiviral therapies could reduce the morbidity and mortality associated with flaviviral infections, but currently there are no drugs available for treatment. In this study, a high-throughput screening assay for the Dengue protease was employed to screen similar to 120,000 small molecule compounds for identification of inhibitors. Eight of these inhibitors have been extensively analyzed for inhibition of the viral protease in vitro and cell-based viral replication using Renilla luciferase reporter replicon, infectivity (plaque) and cytotoxicity assays. Three of these compounds were identified as potent inhibitors of DENV and WNV proteases, and viral replication of DENV2 replicon and infectious RNA. Fluorescence quenching, kinetic analysis and molecular modeling of these inhibitors into the structure of NS2B-NS3 protease suggest a mode of inhibition for three compounds that they bind to the substrate binding pocket. (C) 2016 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据